key: cord-0725627-th8gc6ie
authors: Greuel, Selina; Ihlow, Jana; Dragomir, Mihnea-Paul; Streit, Simon; Corman, Victor Max; Haberbosch, Linus; Winkler, David; Meinhardt, Jenny; Aschman, Tom; Schneider, Julia; Trotsyuk, Iryna; Kunze, Catarina Alisa; Maurer, Lukas; Radbruch, Helena; Heppner, Frank L.; Horst, David; Elezkurtaj, Sefer
title: COVID-19: Autopsy findings in six patients between 26 and 46 years of age
date: 2021-06-03
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.05.069
sha: e615580ce2973c59327c2252047e85a78c62a5b1
doc_id: 725627
cord_uid: th8gc6ie

Objectives Studies on the coronavirus disease 2019 (COVID-19) usually focus on middle aged and older adults. However, younger patients may present with severe COVID-19 and potentially fatal outcomes. For optimized, more specialized therapeutic regimens in this particular patient group, a better understanding of underlying pathomechanisms is of uttermost importance. Methods This study investigates relevant pre-existing medical conditions, clinical histories and autopsy findings, together with SARS-CoV-2-RNA, determined by qPCR, and laboratory data in six COVID-19 decedents at an age of 50 years or younger who were autopsied at the Charité University Hospital. Results From a total of 76 COVID-19 patients who underwent an autopsy at our institution, 6 (7.9%) were 50 years old or younger. Most COVID-19 decedents of younger age presented with pre-existing medical conditions prior to SARS-CoV-2 infection. These included overweight and obesity, arterial hypertension, asthma, obstructive sleep apnea as well as graft-versus-host disease following cancer and bone marrow transplantation. Furthermore, clinical histories and autopsy results revealed a disproportionally high prevalence of thromboembolism and ischemic organ damage in this patient cohort. Histopathology and laboratory results indicated coagulopathies, signs of immune dysregulation and liver damage. Conclusions In conclusion, pre-existing health conditions may increase the risk of severe and fatal COVID-19 in younger patients who may be especially prone to developing thromboembolic complications, immune dysregulation and liver damage.

The coronavirus disease 2019 (COVID-19) pandemic has caused more than two million deaths worldwide, mainly due to severe respiratory and vascular symptoms (Berlin et al., 2020; WHO report, 2020) . Most studies are focused on middle aged and older adults, who are particularly endangered by the virus and are more likely to suffer from serious, life-threatening courses of disease (Guan et al., 2020; Morley et al., 2020) . However, also younger patients with no to very few pre-existing health conditions may be critically affected by severe acute respiratory syndrome virus type 2 (SARS-CoV-2) infections accompanied by serious health conditions and potentially fatal outcomes. For example, Gunasekaran et al. (2020) described a case of a 40-year-old female without any known pre-existing medical condition, who was tested positive for SARS-CoV-2, presented with flu-like symptoms and during the course of the disease and suffered from a large right middle cerebral artery infarction. Another case report described the occurrence of fatal eosinophilic myocarditis in a 17-year old male without pre-existing medical conditions (Craver et al., 2020) . However, such cases appear to be rare, and little is known about COVID-19 pathomechanisms, courses of disease and causes of death in younger adults.

Therefore, in this study we investigated relevant pre-existing medical conditions, clinical histories and autopsy findings of six COVID-19 deceased patients at an age of 50 years or younger. We include data on SARS-CoV-2 RNA in lung tissue as well as key laboratory values to analyze potential underlying pathomechanisms of the disease.

This study includes all patients aged 50 years or younger, who were hospitalized and died 

Clinical data was extracted from available patient records and clinical death certificates. We selected data on clinical causes of death as mentioned on the clinical death certificate, age, sex, onset of symptoms and documented pre-existing health conditions as well as laboratory parameters relevant for coagulation, inflammation and liver damage.

J o u r n a l P r e -p r o o f For PCR analysis of SARS-CoV-2 ribonucleic acid (RNA) in tissue samples, native tissue material, unfixed and, if possible, non-cryopreserved was used. For RNA isolation and purification, the 

In this study, we performed autopsies on patients that died after COVID-19 disease with confirmed SARS-CoV-2 infection. Of all 76 SARS-CoV-2 positive autopsy cases between 1 st of March 2020 and 31 st of January 2021, six individuals met the age requirement, accounting for a total of 7.9 %.

Of these six decedents, three were male and three were female. The median age at death was 31.5 years (range 26 -46 years), the median time from onset of COVID-19 symptoms to death was 18 days, ranging from 16 to 181 days (95 % CI 15-6 -20.4 days, Figure 1A ).

Additional information on the clinical presentation, symptoms, relevant pre-existing medical conditions and the course of disease were available for all cases (Tables 1 and 2 ). Prior to death, all patients presented with COVID-19 related pulmonary symptoms and respiratory failure. Despite being of younger age, 83 % (n = 5/6) of the included patients had pre-existing chronic medical conditions. Of these patients, 50 % were overweight (n = 3/6), and one decedent fulfilled the criteria for obesity (n = 1/6). Chronic respiratory diseases were present in half of the cohort, since two patients suffered from bronchial asthma (n = 2/6) and one patient had a history of obstructive sleep apnea (n = 1/6). Furthermore, three patients showed cardiovascular conditions, such as arterial hypertension (n = 1/6), dilated cardiomyopathy with a pre-existing left ventricular thrombus J o u r n a l P r e -p r o o f (n=1/6) and a history of pulmonary thromboembolism (n =1/6). One patient presented with a history of Ewing sarcoma followed by chemotherapy and chemotherapy-related complications (n = 1/6). The cohort also comprised one patient with chronic anxiety disorder and consecutive use of benzodiazepines (n = 1/6). Notably, one patient presented without pre-existing chronic disease.

During hospitalization, acute pulmonary thromboembolism was detected in two patients, more precisely in the patient without previous symptoms and in the patient with a history of pre-existing dilated cardiomyopathy with cardiac thrombus (n = 2/6). The decedent with previous asthma and obesity suffered from right ventricular heart failure and acute inflammatory cardiomyopathy (n = 1/6). Acute liver failure did occur in three patients (n = 3/6). More precisely, the patient presenting with pre-existing Ewing sarcoma suffered from an acute hepatic graft-versus-host disease with restricted liver function. Another patient developed signs of secondary sclerosing cholangitis and the third patient who had presented with asthma-patient and obesity developed liver ischemia due to a stenosis of the celiac trunk. Acute renal failure co-occurred in four of the six patients.

All deaths occurred in the intensive care unit (ICU). Median time from admission to ICU to death was 15.5 days (range 6 -123 days). In most individuals (n = 5/6), invasive ventilation as well as extracorporeal membrane oxygenation were documented as part of intensive patient care.

Immediate causes of death as documented in the clinical death certificates were septic multi organ failure (n = 2/6), mesenteric ischemia (n = 1/6), acute liver failure (n = 1/6), hemorrhagic shock (n = 1/6) and cardiogenic shock (n = 1/6). More detailed information on conditions leading to immediate causes of death and death-related underlying diseases can be found in Table 1 .

In order to comprehend the clinically described comorbidities, courses of disease and causes of death, we performed full body autopsies on all six decedents. We defined immediate causes of death, conditions leading to cause of death and underlying causes based on pathological findings upon autopsy combined with the clinical data in each case ( Table 2) .

In three cases, (septic) multi organ failure was identified as immediate cause of death (n = 3/6). In the other three cases, we found acute mesenteric ischemia (n = 1/6), heart failure (n = 1/6), or hemorrhagic shock (n = 1/6) to be the immediate cause of death. As conditions leading to cause of death, we identified COVID-19 pneumonia (n = 1/6), invasive pulmonary mycosis (n = 2/6) with intestinal Graft-versus-Host disease (n = 1/6), disseminated arterial thrombosis (n = 1/6), cholangitis with liver failure (n = 1/6) and surgically treated pleural empyema (n = 1/6). As underlying causes, we found COVID-19 pneumonia to be most prevalent (n = 4/6), followed by dilated cardiomyopathy (n = 1/6) and history of chemoradiotherapy for Ewing sarcoma (n = 1/6).

Other relevant macroscopically detected disease conditions included adipositas per magna (n = 1/6), cardiac apical thrombus (n = 1/6), mild atherosclerosis (n = 1/6), splenomegaly (n = 1/6) and hepatomegaly (n = 2/6). In combination, evidence of pre-existing chronic disease was present in five out of six younger COVID-19 decedents determined by autopsy.

Ante-mortem laboratory parameters revealed a constellation of (acute) liver damage, coagulopathy, anemia and general inflammation (Figure 2 C + D).

Post-mortem histopathology revealed thrombosis and/or ischemic organ damage in one or more organ systems in four, and severe bleeding in two out of six patients (Table 2, Figure 1B , Figure 2 E + F). Furthermore, we found fungal and/or parasitic infections in two out of the six patients, including pulmonary aspergillosis (n = 2/6) and cerebral toxoplasmosis (n = 1/6, Figure 2 A + B, Figure 3 E + F), indicating immunodeficiency. Also, we observed one case with lymphocytic myocarditis (n = 1/6, Figure 3B ). Besides acute symptoms, we also found indicators for chronic metabolism-induced damage, such as hepatic steatosis (n = 2/6), mild to moderate atherosclerosis (n = 2/6), coronary artery sclerosis (n = 1/6) as well as chronic right heart damage (n = 1/6) in four out of six patients. 

The fourth patient in our cohort was 33-years of age and did not have any known chronic disease prior to SARS-CoV-2 infection. The patient presented with a lung empyema and subsequently underwent surgery with pleural decortication. However, during the course of the disease, a pulmonary thromboembolism was diagnosed, which was treated with anticoagulation.

Consequently, he developed a hematothorax resulting in fulminant deterioration and death.

Although this patient presented without pre-existing medical conditions, the fatal outcome in this case can be attributed to a treatment-associated major adverse event.

Furthermore, our cohort included a 45-year-old patient who presented with flu-like symptoms, fever up to 39.5 degrees Celsius, dry cough, headache and myalgia. During the disease, she developed an acute respiratory distress syndrome and required invasive ventilation. Despite maximum therapeutic efforts her condition worsened, she developed acute liver failure and septic multi organ failure. Upon histopathological analysis following autopsy, we found evidence of thrombotic vascular occlusion in different organ systems, including lung, heart, kidneys, the small intestine, and brain (Figure 2 F) .

Lastly, the cohort also contained one patient (46 years) with chronic anxiety disorder and abuse of benzodiazepines. Despite the patient's meticulous efforts of self-isolation, he was infected with SARS-CoV-2. Known pre-existing medical conditions were a dilated cardiomyopathy with highly reduced left ventricular ejection fraction (LVEF 15 %), as well as a pre-existing chronic cardiac apical thrombus ( Figure 3C ) and a pulmonary thromboembolism which he developed during the cause of the disease ( Figure 2E ). After initial signs of recovery, the patient's respiratory and cardiac function declined, and he died from cardiogenic shock. , 2020) , may lead to a hypercoagulable state, as described by Pourafkari et al. (2021) . Furthermore, it can be discussed that in younger adults, who generally present in better health than older adults, more severe complications (such as thromboembolic events) are required to cause fatal outcomes. Vice versa, older adults might succumb more easily to less severe complications.

A limitation of this study is the small sample size, which might have led to a selection bias towards younger patients with particularly severe COVID-19 and therefore in need for special intensive care admission. Additionally, autopsies might have been predominantly requested in patients with complicated or unforeseen clinical courses of disease. Larger cohort studies including control groups would be necessary for future validation of our results and for the determination of differences between age-related subgroups of COVID-19 deceased.

In conclusion, all of the younger COVID-19 decedents in our cohort except one presented with pre-existing chronic medical conditions prior to SARS-CoV-2 infection, including obesity, OSA and hypertension. These comorbidities most probably have influenced the course of disease in these patients. Furthermore, our data suggests that younger SARS-CoV-2 infected adults may be particularly prone to thromboembolism and ischemic organ damage, as well as coagulopathies, immune dysregulation, and acute liver damage. The specific case histories emphasize that (i) 

COVID-19-associated vasculitis and vasculopathy

Pathophysiology of SARS-CoV-2: targeting of endothelial cells renders a complex disease with thrombotic microangiopathy and aberrant immune response. The Mount Sinai COVID-19 autopsy experience

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

Fatal Eosinophilic Myocarditis in a Healthy 17-Year-Old Male with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2c)

Causes of Death and Comorbidities in Patients with COVID-19

Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study

Does eNOS derived nitric oxide protect the young from severe COVID-19 complications?

Stroke in a young COVID-19 patient

Thrombosis in COVID-19

Asthma and COVID-19: What do we know now. Clinical medicine insights

Post-Mortem Diagnosis and Autopsy Findings in SARS-CoV-2 Infection: Forensic Case Series

SARS-CoV-2-Induced Kawasaki-Like Hyperinflammatory Syndrome: A Novel COVID Phenotype in Children

Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis

COVID-19 and Hyperinflammatory Syndrome in Children: Kawasaki Disease with Macrophage Activation Syndrome in Disguise?

Potential influences of obstructive sleep apnea and obesity on COVID-19 severity

Editorial: COVID-19 and Older Adults

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

Obesity -a risk factor for increased COVID-19 prevalence, severity and lethality (Review)

Clinical Experience, Pathophysiology, and Considerations in the Prophylaxis and Treatment of Hypercoagulopathy of COVID-19: A Review Study

Collection and Submission of Postmortem Specimens from Deceased Persons with Confirmed or Suspected COVID-19 -Interim Guidance

Hyperinflammatory shock in children during COVID-19 pandemic

Viral presence and immunopathology in patients with lethal COVID-19: a prospective autopsy cohort study

Obesity and impaired metabolic health in patients with COVID-19

COVID-19 and arterial hypertension: Hypothesis or evidence

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

World Health Organization (WHO) 2020. Coronavirus Disease (COVID-19) Situation Report of the World Health Organization-Weekly Epidemiological Update

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study

Virological assessment of hospitalized patients with COVID-2019

Association of asthma and its genetic predisposition with the risk of severe COVID

Severe acute respiratory syndrome coronavirus type 2 (SARS CoV-2), Coronavirus disease 2019 (COVID-19), cytomegalovirus (CMV), human herpesvirus 1 (HHV-1), secondary sclerosing cholangitis (SCC), obstructive sleep apnea (OSA), world health organization (WHO), Graft-versus-Host disease, therapy-induced myelodysplastic syndrome (t-MDS), allogeneic hematopoietic stem cell transplantation (allo-HSCT)

All authors declare that they have no conflicts of interest with regard to this work. 

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.